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The P13 potential is the rodent equivalent of the P50 potential, which is an evoked response 
recorded at the vertex (Vx) 50 ms following an auditory stimulus in humans. Both the P13 
and P50 potentials are only present during waking and rapid eye movement (REM) sleep, and 
are considered to be measures of level of arousal. The source of the P13 and P50 potentials 
appears to be the pedunculopontine nucleus (PPN), a brainstem nucleus with indirect ascending 
projections to the cortex through the intralaminar thalamus, mediating arousal, and descending 
inhibitory projections to the caudal pontine reticular formation (CPRF), which mediates the 
auditory startle response (SR). We tested the hypothesis that intracranial microinjection (ICM) 
of glutamate (GLU) or GLU receptor agonists will increase the activity of PPN neurons, resulting 
in an increased P13 potential response, and decreased SR due to inhibitory projections from 
the PPN to the CPRF, in freely moving animals. Cannulae were inserted into the PPN to inject 
neuroactive agents, screws were inserted into the Vx in order to record the P13 potential, 
and electrodes inserted into the dorsal nuchal muscle to record electromyograms and SR 
amplitude. Our results showed that ICM of GLU into the PPN dose-dependently increased 
the amplitude of the P13 potential and decreased the amplitude of the SR. Similarly, ICM of 
N-methyl-d-aspartic acid or kainate into the PPN increased the amplitude of the P13 potential. 
These findings indicate that glutamatergic input to the PPN plays a role in arousal control in vivo, 
and changes in glutamatergic input, or excitability of PPN neurons, could be implicated in a 
number of neuropsychiatric disorders with the common symptoms of hyperarousal and REM 
sleep dysregulation.
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(Miyazato et al., 1999b; Teneud et al., 2000; Mamiya et al., 2005). 
Furthermore, decreasing arousal levels through the use of anesthet-
ics, ethanol, or head injury decreased the amplitude of the P13 
potential (Miyazato et al., 1999a).
The PPN receives glutamatergic input locally and from other 
mesopontine nuclei. ICM of glutamate (GLU) into the PPN of the 
freely moving rat increased waking and REM sleep (Datta et al., 
2001b). However, ICM into this nucleus of the glutamate receptor 
agonist N-methyl-d-aspartic acid (NMDA) specifically increased 
waking (Datta et al., 2001a), while the glutamate receptor agonist 
kainate (KA) specifically increased REM sleep (Datta, 2002). On 
the contrary, ICM of α-amino-3-hydroxyl-5-methyl-4-isoxazole-
propionate (AMPA) and some metabotropic receptor agonists into 
the PPN had no effect on sleep-wake control (Datta, 2002). The 
PPN contains separate populations of cholinergic, glutamatergic, 
and GABAergic neurons (Wang and Morales, 2009), and a majority 
of PPN neurons project to the intralaminar thalamus (ILT), includ-
ing the parafascicular nucleus (Pf; Sofroniew et al., 1985; Hallanger 
et al., 1987). Descending projections of the PPN include efferents 
to postural and locomotion control systems, including the caudal 
pontine reticular formation (CPRF), which mediates the auditory 
startle response (SR; Davis, 1984; Semba and Fibiger, 1992; Koch 
and Schnitzler, 1997). Inhibitory cholinergic projections from the 
IntroductIon
The P50 potential is a midlatency auditory evoked response recorded 
at the vertex (Vx) and occurs approximately 40–70 ms following 
an auditory click stimulus (Picton et al., 1974). The P50 potential 
is present during waking and rapid eye movement (REM) sleep, 
but not during slow-wave sleep (SWS; Erwin and Buchwald, 1986), 
and is blocked by the cholinergic receptor antagonist scopolamine, 
suggesting that may be mediated, at least in part, by cholinergic 
neurons (Buchwald et al., 1991). The P13 potential in the freely 
moving rat occurs 11–15 ms following a click stimulus, is only 
present during waking and REM sleep, is blocked by scopolamine 
(Miyazato et al., 1995), and appears to be the rodent equivalent 
to the human P50 potential (Miyazato et al., 1995, 1996, 1999a,c; 
Teneud et al., 2000). Furthermore, both the P13 and P50 poten-
tials are considered to be measures of level of arousal (Garcia-Rill 
et al., 2002).
The source of the P13 potential has been localized to the pedun-
culopontine nucleus (PPN), which is the cholinergic arm of the 
reticular activating system (RAS). PPN neurons are most active 
during waking and REM sleep (Datta and Siwek, 2002), that is, 
when the P13 potential is manifested. Intracranial microinjection 
(ICM) of inhibitory neuroactive agents into the PPN decreased 
the amplitude of the P13 potential in a dose-dependent manner 
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extended above the cement. The end of each cannula was fitted with 
a plastic cap and stylette to close off the open end of the cannula 
and prevent internal blockage of the cannula.
The skin was closed with suture around the receptacle. After sur-
gery, animals were given 0.2 mL Penicillin G (IM), and 5 mL saline 
(subcutaneous), to prevent infection and dehydration. Additionally, 
0.2 mL Bupronex was administered for pain management. Animals 
were placed in an intensive care neonatal incubator maintained at 
37°C during recovery. Rats were housed individually to prevent 
damage of the receptacle in a vivarium with a 12/12 light dark 
schedule, with lights on from 6 AM to 6 PM. Food and water were 
available ad libitum, and animals recovered for 7 days.
recordIng procedures
We used a sound-attenuating chamber (40 cm × 40 cm × 40 cm 
internal dimensions) with two speakers centered on opposite walls 
10.6 cm above the floor to create a diffuse sound field within the 
chamber. Auditory stimuli, in the form of 100 μs rectangular pulse 
clicks, were presented at various decibel levels by a Grass Instruments 
Click-Tone module (Grass Instruments, Model S10ASCM, West 
Warwick, RI, USA) to the speakers. Measurements were made in 
the chamber using a sound level meter set for a 32- to 10,000-Hz 
range and in averaging mode. The click stimulus was produced at 
99.9 Hz (fastest setting on the S10CTCM) in the recording chamber 
with the door open. Measurements were: (1) 103 dB sound pres-
sure level (SPL) at the speaker on one side and 102 dB SPL on the 
other, (2) 84 dB SPL at the center of the chamber, and 82 dB SPL 
at the back corners, all at 4.25 in above the floor of the recording 
chamber. All stimulus levels were well above the threshold of the 
P13 potential that was measured as ∼70 dB SPL at the center of the 
chamber (Miyazato et al., 1995, 1996, 1999a,c; Teneud et al., 2000). 
The chamber was equipped with a fan that provided both continu-
ous airflow and white noise background (60 dB SPL), and was lit 
by a 12-V, 20-W bulb. Wires from a commutator swivel (Dragonfly, 
Model SL-10, Ridgeley, WV, USA) at the top of the chamber were 
connected to a plug that was inserted into the nine-pin receptacle 
affixed to the animal’s skull.
Recordings began after a 7-day recovery period. Rats were 
accommodated to the chamber before and after surgery. All 
responses were recorded from unrestrained, alert rats before and 
after treatment with saline (control, CTL), GLU, NMDA, or KA. 
During some experiments, animals were pretreated with the NMDA 
receptor antagonist 2R-amino-5-phosphonovaleric acid (AP5) or 
the KA receptor antagonist γ-d-glutamylaminomethylsulfonic acid 
(GAMS) 15 min prior to ICM of receptor agonists into the PPN. 
Recordings were made from the Vx and neck muscles (EMG). 
Individual waveform acquisition began 50 ms before the first set 
of clicks to ensure adequate baseline acquisition and continued 
655 ms after the first stimulus. Click stimuli were presented every 
5 s until 32 potentials were acquired for averaging using SuperScope 
software (GW Instruments, Somerville, MA, USA).
Following a 15-min acclimation period to the chamber, three 
control recordings of evoked potentials and SRs began for each 
animal in each session. Experimental recordings began following 
injection at 3 min intervals for 15 min (to detect rapid changes at 
the beginning of each treatment), and then at 10 min intervals for 
30 min (45 min total).
PPN to the CPRF serve to modulate the response of CPRF neurons 
following an auditory stimulus (Hoffman and Ison, 1980; Koch 
and Schnitzler, 1997).
We tested the hypothesis that ICM of GLU or its agonists will 
increase the activity of PPN neurons, resulting in increased arousal, 
as manifested by an increase in the amplitude of the P13 potential 
following an auditory stimulus. Furthermore, increased activity 
in the PPN will result in increased inhibition of the CPRF, and a 
decrease in the SR following an auditory stimulus.
MaterIals and Methods
All experimental protocols were approved by the Institutional 
Animal Care and Use Committee of the University of Arkansas 
for Medical Sciences, and were in agreement with the National 
Institutes of Health guidelines for the care and use of laboratory 
animals.
surgIcal preparatIon
Adult male Harlan Sprague Dawley rats (220–300 g, n = 32) were 
anesthetized with ketamine (60 mg/kg) and xylazine (10 mg/kg) 
IM. Males were used to avoid potential effects of the estrous cycle 
on the responses observed. Anesthesia was maintained such that the 
withdrawal reflex to paw pinch was absent, and body temperature 
was maintained at 37°C by a water circulating heating pad and rectal 
thermometer with automatic heat lamp. Animals were placed in a 
stereotaxic holder using hollow ear bars that protected the middle 
ear from damage. After reflection of the scalp and right temporalis 
muscle, coordinates were marked for electrode placement (Paxinos 
and Watson, 1998).
Holes were drilled in the skull with a manual micro pin vise, and 
two stainless steel screws (1/8″ long, size #0–80) for recording poten-
tials were inserted epidurally at the Vx (midway between virtual 
lambda and bregma, 1.0 mm lateral from the midline, bilaterally). 
The Vx potential was recorded with reference to a screw inserted 
into the right frontal sinus. An additional screw was inserted in 
the left occipital bone and cemented to the skull for reinforcement 
of the structure. Two pairs of insulated wires with 1 mm exposed 
ends for recording electromyograms (EMGs) were inserted into the 
dorsal nuchal muscle. A ground wire was placed subcutaneously 
in the dorsal neck. Electrodes were connected by Teflon insulated 
wires to a nine-pin receptacle cemented to the skull with dental 
resin and acrylic mixture (Stoelting Co., IL, USA). EMG wires and 
the ground were connected to the same receptacle. Dental cement 
was then used to fasten the receptacle to the skull and to insulate 
and protect the connections.
In addition, a pair of 25 gage stainless steel hypodermic tubing 
guide cannulae (18 mm length) was implanted bilaterally. Holes 
just large enough to allow passage of the hypodermic tubing were 
drilled into the skull at coordinates 1.0 mm anterior of the inter-
aural line and 1.9 mm lateral of the midline (Paxinos and Watson, 
1998). Cannulae were inserted into the holes and a stereotaxic 
micropositioner was used to position the lower end of each can-
nula at 6.0 mm above the horizontal plane passing through the 
interaural line (1.0 mm dorsal to the PPN). This placement was 
used in order to minimize cell damage in the PPN. The tops of the 
cannulae extended about 1 cm above the top of the skull and were 
cemented in place so that approximately 0.5 cm of the cannulae 
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MeasureMent technIques
Measurement of the P13 potential amplitude was made from the 
largest positive deflection between 11 and 13 ms (latency) to its 
beginning (foot) or the peak of the preceding negative deflection 
(N
B
). Trials in which the foot or N
B
 of the P13 potential was indis-
cernible or absent, measurement was made from baseline at 0 ms. 
The time to peak of the P13 potential is 4–5 ms (Miyazato et al., 
1995). The maximum amplitude of the rectified and averaged EMG 
above prestimulus baseline was measured as the SR at its peak 
latency of 6–9 ms.
In experiments involving acute treatments, the two most simi-
lar of the three pretreatment control values were averaged and 
designated as 100%. Subsequent post-injection amplitudes were 
calculated as a percentage of the averaged control recording. Thus, 
each test response was normalized to its own controls.
To control for variability among control values between ani-
mals, we also employed a “difference” measurement technique for 
assessing the effects of treatment on the P13 potential response 
during and after treatment. For this measurement, the amplitude 
of the control P13 potential was subtracted from the amplitude 
of the post-treatment P13 potential for each time point. This 
allowed for the effect of the treatment to be expressed in terms of 
“direction” (positive or negative) and degree (actual difference in 
microvolts).
data analysIs and statIstIcal Methods
In these studies, each animal was injected with either saline (CTL) 
or one of four drug concentrations. Individual animals were then 
recorded at specific and consecutive time points following injection. 
In addition, each animal was tested multiple times (once/week) 
and received a different injection treatment in each testing session 
(no more than five neuroactive compounds and six testing sessions 
total). Therefore, there were multiple sampling measures for each 
animal. Because of the experimental design, repeated measures 
analysis of variance (ANOVA) was an appropriate statistical model 
because it is a type of factorial experiment that is capable of exam-
ining and comparing response trends over time and adjusting for 
multiple sampling error.
The amplitude and habituation of the P13 potential and SR for 
each animal was analyzed. Data were tested for normality using 
the Kolmogorov–Smirnov test. Repeated measures ANOVA was 
used to determine main effects and interactions of drug condi-
tion and time, where drug condition and time post-injection were 
designated independent variables. The study evaluated influences 
of drug condition and time post-injection on the P13 potential 
and SR amplitude. For this purpose, the averages of the response 
to saline were compared to the averages of the response to drug at 
each time point with amplitude designated the repeated measure. 
Significant main effects were tested with post hoc within subject 
comparisons. The Newman–Keuls test was used for its strength of 
analysis of unequal number of samples between groups as well as 
repeated measures.
One-way ANOVA was applied to the experimental paradigm 
to compare the difference in means between CTL samples and 
experimental samples at each time point, as well as differences 
between time points, for each individual drug concentration 
group. For example, one-way ANOVA was used to compare 
Potentials and SRs were amplified using Grass preamplifiers (Grass 
Instruments, Model P511K, West Warwick, RI, USA) with high imped-
ance probes (Grass HIP5). Vx signals were amplified 20 K times and 
filtered at 1 Hz–0.1 kHz before being digitized using an InstruNet 
model 100 B (GW Instruments, Somerville, MA, USA) analog to digital 
converter. EMGs were amplified 5K times, filtered at 300 Hz–10 kHz 
and rectified before averaging to obtain the SR. Recordings were digi-
tized at a rate of 10 kHz and stored. Animals were tested between 8 
AM and 1 PM to control for possible time of day effects.
IcM technIques
After pre-injection recordings were made, animals received bilateral 
injections using a 32-gage stainless steel tube (19 mm length) to 
extend 1.0 mm beyond the lower end of the guide cannulae (dor-
sal boundary of the PPN). Vehicle for all injected substances was 
0.9% physiological saline. The injectors were connected to a 5-μL 
Hamilton (Hamilton Comp., Reno, NV, USA) syringe by a 10-cm 
flexible polyethylene (PE) tube (0.38 mm ID). Before injection, 
the PE tubing was checked to ensure a firm seal around the syringe 
to prevent leakage from the tip of the PE tube. A small air bubble 
was introduced into the PE tubing to monitor the movement of 
fluid during injection. Concentrations of injected solutions were 
adjusted so that each injection was 0.1 μL.
Injections were delivered over 10–20 s while the animals were 
gently held. The junction of the tubing and the injector was also 
sealed and checked for leakage during the injection. The pressure 
from 0.1 μL injection was negligible and unlikely to disturb the seal 
of the PE tubing. The animal was returned to the recording chamber 
within 2 min of the beginning of the injections, and recordings 
began immediately.
All concentrations used were based on previous reports of toler-
able and non-excitotoxic ICM concentrations that did not cause 
excessive agitation or locomotion (Datta and Siwek, 1997; Datta 
et al., 2001a,b; Datta, 2002; Kobayashi et al., 2004). GLU was injected 
in concentrations of 0.06, 0.16, 0.30, and 0.48 nmol. AP5 and GAMS 
were tested at 0.16, 0.30, 0.48 nmol. NMDA was tested at 0.025, 0.05, 
0.10, 0.30, and 1.00 mmol. KA was tested at 10, 20, and 30 μmol. 
Injections of saline, GLU, AP5, GAMS, NMDA, or KA were carried 
out in random order, and no animal was treated more than once/
week (to obtain complete washout of treatment) or given more 
than five neuroactive injections overall (to ensure prevention of 
desensitization or additive neuronal excitotoxicity).
threshold deterMInatIon
The threshold for the P13 potential has been described in rats 
(Miyazato et al., 1995, 1999b,c), and determined by deliver-
ing click stimuli at intensities of 50–103 dB. This procedure 
was used to confirm that the animals’ hearing was not affected 
by preparatory procedures, and to verify that all animals used 
exhibited similar sensitivity to the auditory stimuli. This deter-
mination was made once for each animal used in these experi-
ments. Previous studies in our lab have shown that the average 
threshold for eliciting P13 potentials for SD rats is 70 ± 2 dB SPL, 
and animals that varied more than ±5 dB SPL were excluded 
from testing (Miyazato et al., 1995, 1996, 1999a,c; Teneud et al., 
2000). All auditory stimuli for testing were delivered at 103 dB 
to ensure suprathreshold activation of the P13 potential.
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buffered  solution. After fixation, the brain was carefully removed 
from the skull and immersed in 20% sucrose overnight. The brain-
stem was dissected free and frozen in medium for sectioning using 
a Vibratome Ultra Pro 5000 Cyrostat.
nIcotInaMIde adenIne dInucleotIde phosphate dIaphorase
Twenty micromolar sections were cut in the sagittal plane and 
collected in phosphate buffer containing 1 mM MgCl and proc-
essed histochemically for reduced nicotinamide adenine dinucle-
otide phosphate (NADPH)-diaphorase (which selectively labels 
PPN neurons; Vincent et al., 1983). Histological reconstruction 
of the locations of the NADPH-diaphorase-positive neurons in 
relation to the lesion allowed the injection site to be located, 
and confirmed that injections had been made into the PPN as 
defined by the region of NADPH-diaphorase-positive neurons. 
Data from animals in which the injection site overlapped the 
NADPH-diaphorase-positive neurons were correlated with the 
electrophysiological data, and only these animals were included 
in analysis.
results
InjectIon sItes, p13 potentIal, and startle response
Figure 1A shows a representative Vx recording of the P13 poten-
tial and SR from a single animal following ICM of saline. Note the 
presence of the P13 potential (filled circle) and SR (filled star). 
Following ICM of 0.16 nmol GLU into the PPN (Figure 1B), 
the P13 amplitude increased (open circle), and the SR decreased 
(open star) compared to saline. Injection sites were similar to 
those previously reported in our lab (Miyazato et al., 1999b, 
2000a; Teneud et al., 2000). Figure 1C shows a photomicrograph 
of a sagittal section through the PPN, which is labeled using 
NADPH-diaphorase histochemistry. The injection cannula pro-
truded beyond the guide cannula, with its tip at the dorsal edge 
of the PPN (X).
response means of GLU 0.06 nmol CTL vs. GLU 0.06 nmol 5 min, 
GLU 0.06 nmol 10 min, etc. Two-way ANOVA was applied to 
the experimental paradigm to compare the difference in means 
between samples of a specific time point of one experimen-
tal group and the same time point of a separate experimental 
ground. For example, two-way ANOVA was used to compare 
response means of GLU 0.06 nmol 10 min post-injection vs. 
saline 10 min post-injection, etc.
Data sets that failed the normality test were analyzed using the 
Kruskal–Wallis test followed by Dunn’s Multiple Comparisons post-
tests. Differences were considered significant at p-values ≤ 0.05. 
Depending on the complexity of the analysis required, GB-State®, 
GraphPad InStat3®, or SAS® software was used for data analysis.
power analysIs
We based our calculations on eight animals per ground using previ-
ously published data. Four similar P13 potential studies (Miyazato 
et al., 1999a,c, 2000a,b) showed maximum differences of three to 
fourfold (average = 69%) between the control and experimental 
treatments with an average SE of 9.2%. Thus, for p = 0.05 we had a 
power of 0.95 to detect these robust differences (0.89 for p = 0.01) 
between control and experimental treatments, and only a 5% 
chance of committing a type II error in the proposed studies.
hIstologIcal procedures
After the completion of experiments, the site of intracranial injec-
tions was verified with electrolytic lesion. For lesioned subjects, the 
animal was anesthetized, and 19 mm insulated electrode (except 
1 mm at the tip) was inserted into each guide cannulae. A lesion 
at the injection site (1 mm beyond the tip of the cannula) was 
created by applying a 0.5-mA DC current to the electrode for 
2 s using a Grass stimulator (Model S88 with constant current 
unit). After lesioning, the animal was perfused transcardially using 
heparinized saline and 4% paraformaldehyde in 1.0 M phosphate 
Figure 1 | representative P13 potential and Sr recording: (A) 
Representative recordings of the P13 potential and SR from a single animal 
following ICM of saline. Note the presence of the P13 potential (filled circle) and 
SR (filled star). (B) Following ICM of 0.16 nmol GLU into the PPN (Figure 1B), 
the P13 potential amplitude increased (open circle) and SR amplitude decreased 
(open star) compared to saline. (C) Photomicrograph of a sagittal section 
through the PPN. The injection cannula protruded beyond the guide cannula, 
with its tip at the dorsal edge of the PPN (X).
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amplitude following ICM at each time point (Figure 2B). One-way 
repeated measures ANOVA and post hoc testing comparing CTL 
vs. each concentration of GLU revealed a statistically significant 
increase in P13 potential amplitude between CTL and 0.16 nmol 
at 15 min (p < 0.05, F = 2.91, df = 8) post-injection; between CTL 
and 0.30 nmol at 5 and 45 min (p < 0.05) and 10–35 min (p < 0.01, 
F = 5.42, df = 7) post-injection; and between CTL and 0.48 nmol at 
10, 15, and 25 min (p < 0.01, F = 9.64, df = 7) post-injection. ICM 
of saline did not result in any significant change in P13 potential 
amplitude at any time point (ns, F = 0.83, df = 16).
The effect of GLU microinjection into the PPN on SR amplitude 
was also measured (Figure 3). Figure 3A shows the mean and SE of the 
amplitude of the SR following ICM of saline (n = 9), 0.06 nmol GLU 
(n = 7), 0.16 nmol GLU (n = 7), 0.30 nmol GLU (n = 7), and 0.48 nmol 
(n = 7). Two-way repeated measures ANOVA with factors of time 
and drug concentration and post hoc testing comparing saline vs. each 
effects of glu on the p13 potentIal and sr
To test the effects of GLU ICM into the PPN on the amplitude of the 
P13 potential, saline and four concentrations of GLU were injected 
into the PPN and P13 potential amplitude was measured following 
auditory stimulation. Figure 2A shows the mean (calculated as 
the difference in amplitude at each time point from its own pre-
injection CTL) and SE of the amplitude of the P13 potential fol-
lowing ICM of saline (n = 17), 0.06 nmol GLU (n = 10), 0.16 nmol 
GLU (n = 9), 0.30 nmol GLU (n = 8), and 0.48 nmol GLU (n = 8). 
Two-way repeated measures ANOVA with factors of time and drug 
concentration and post hoc testing comparing saline vs. each con-
centration of GLU revealed a statistically significant increase in the 
P13 potential amplitude compared to saline following 0.48 nmol 
GLU at 10 min (p < 0.05) and 15 min (p < 0.01, F = 3.13, df = 7) 
post-injection. Further statistical testing was performed to com-
pare the CTL P13 potential amplitude (before ICM of GLU) to the 
Figure 2 | intracranial microinjection of gLu into the PPN increased the 
amplitude of the P13 potential: (A) Mean amplitude difference (μV) from CTL 
amplitude recorded before injection (CTL) and following injection at 5, 10, 15, 25, 
35, and 45 min. Averages after saline (black, n = 17), 0.06 nmol GLU (red, 
n = 10), 0.16 nmol GLU (blue, n = 9), 0.30 nmol GLU (green, n = 8), and 
0.48 nmol GLU (pink, n = 8). Significance is denoted for two-way ANOVA 
between groups comparison. Note the significant increases in P13 potential 
amplitude compared to saline at 10 and 15 min after 0.48 nmol GLU (*p < 0.05, 
**p < 0.01). (B) Mean amplitude difference (μV) from CTL amplitude recorded 
before injection (CTL), and following injection at 5, 10, 15, 25, 35, and 45 min. 
Averages after saline (black, n = 17), 0.16 nmol GLU (blue, n = 9), 0.30 nmol GLU 
(green, n = 8), and 0.48 nmol GLU (pink, n = 8). Significance is denoted for 
one-way ANOVA for within subject comparison. Note the significant increases in 
P13 potential amplitude compared to CTL at 15 min after 0.16 nmol GLU; 
5–45 min after 0.30 nmol GLU; and 10, 15, and 25 min after 0.48 nmol GLU 
(*p < 0.05, **p < 0.01).
Frontiers in Neurology | Sleep and Chronobiology  January 2011 | Volume 2 | Article 3 | 6
Simon et al. Glutamatergic effects on the P13
auditory stimuli. Figure 4A shows the mean and SE of the amplitude 
of the P13 potential following ICM of saline (n = 17), 0.025 mmol 
NMDA (n = 8), 0.05 mmol NMDA (n = 12), 0.10 mmol NMDA 
(n = 8), 0.30 mmol NMDA (n = 8), and 1.00 mmol NMDA (n = 8). 
Two-way repeated measures ANOVA with factors of time and drug 
concentration and post hoc testing comparing saline vs. each concen-
tration of NMDA revealed a statistically significant increase in the 
P13 potential amplitude following 1.00 mmol NMDA at 10, 15, and 
35 min (p < 0.01, F = 2.66, df = 7) post-injection. Further statistical 
testing was performed to compare the CTL P13 potential amplitude 
(before ICM of NMDA) to amplitude following ICM at each time 
point (Figure 4B). One-way repeated measures ANOVA and post hoc 
testing comparing CTL vs. each concentration of NMDA revealed a 
statistically significant increase in P13 potential amplitude between 
CTL and 0.10 mmol NMDA at 10 and 15 min (p < 0.05, F = 2.31, 
df = 7) post-injection; between CTL and 0.30 mmol NMDA at 10 and 
15 min (p < 0.05, F = 3.31, df = 7) post-injection; and between CTL 
concentration of GLU revealed a statistically significant decrease in SR 
amplitude following 0.16 nmol GLU at 5 min (p < 0.05, F = 2.25, df = 7) 
post-injection, and 0.30 nmol GLU at 5 min (p < 0.05, F = 2.23, df = 7) 
post-injection. Further statistical testing was performed to compare 
the CTL SR amplitude (before ICM of GLU) to the amplitude follow-
ing ICM at each time point (Figure 3B). One-way repeated measures 
ANOVA and post hoc testing comparing CTL vs. each concentration 
of GLU revealed a statistically significant decrease in SR amplitude 
between CTL and 0.16 nmol GLU at 5 and 25 min (p < 0.05, F = 2.59, 
df = 7) post-injection and between CTL and 0.03 nmol GLU at 5, 15, 
and 25 min (p < 0.05, F = 2.34, df = 7) post-injection. ICM of saline 
did not result in any statistically significant change in SR amplitude.
effects of nMda on the p13 potentIal and sr
To test the effects of ICM of NMDA into the PPN on P13 potential 
amplitude, saline and five concentrations of NMDA were injected 
into the PPN, and P13 response amplitude was measured following 
Figure 3 | intracranial microinjection of gLu into the PPN decreased the 
amplitude of the Sr: (A) Mean amplitude difference (μV) from CTL amplitude 
recorded before injection (CTL) and following injection at 5, 10, 15, 25, 35, and 
45 min. Averages after saline (black, n = 9), 0.06 nmol GLU (red, n = 7), 0.16 nmol 
GLU (blue, n = 7), 0.30 nmol GLU (green, n = 7), and 0.48 nmol GLU (pink, n = 7). 
Significance is for two-way ANOVA between groups comparison. Note the 
significant decreases in SR amplitude compared to saline at 5 min following 0.16 
and 0.30 nmol GLU (*p < 0.05, **p < 0.01). (B) Mean amplitude difference (μV) 
from CTL amplitude recorded before injection (CTL), and following injection at 5, 10, 
15, 25, 35, and 45 min. Averages after saline (black, n = 9), 0.16 nmol GLU (blue, 
n = 7), 0.30 nmol GLU (green, n = 7), and 0.48 nmol GLU (pink, n = 7). Significance 
is denoted for one-way ANOVA for within subject comparison. Note the significant 
decrease in SR amplitude compared to CTL at 5 and 25 min following 0.16 nmol 
GLU; and 5, 15, and 25 min following 0.30 nmol GLU (*p < 0.05, **p < 0.01).
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F = 3.05, df = 11) post-injection. One-way ANOVA comparing 
CTL vs. AP5/NMDA revealed no statistically significant differ-
ence in P13 potential amplitude at any time point (ns, F = 1.77, 
df = 4). Therefore, ICM of NMDA increased the amplitude of the 
P13 potential, and this effect was blocked by pretreatment with 
the antagonist AP5.
The effect of ICM of NMDA into the PPN on SR amplitude was 
also measured. Figure 5A shows the mean and SE of the amplitude 
of the SR following saline (n = 9), 0.025 mmol NMDA (n = 5), 
0.05 mmol NMDA (n = 7), 0.10 mmol NMDA (n = 6), 0.30 mmol 
NMDA (n = 6), and 1.00 mmol NMDA (n = 4). Two-way repeated 
measures ANOVA with factors of time and drug concentration 
comparing saline vs. each concentration of NMDA revealed no 
statistically significant decrease in SR amplitude between saline and 
and 1.0 mmol NMDA at 10 and 15 min (p < 0.01, F = 4.82, df = 7) 
post-injection. ICM of saline did not result in any significant change 
in P13 potential amplitude at any time point (ns, F = 0.83, df = 16).
Next, the NMDA receptor antagonist AP5 was injected before 
NMDA. Figure 4C shows the mean and SE of the amplitude of the 
P13 potential following ICM of saline (n = 17), 0.05 nmol NMDA 
(n = 12), 0.16 nmol AP5 (n = 6), and 0.05 mmol NMDA pretreated 
with 0.16 nmol AP5 (n = 5). Two-way ANOVA with factors of time 
and drug and post hoc testing revealed a statistically significant 
increase in P13 potential amplitude following 0.05 mmol NMDA 
at 15 min (p < 0.05, F = 2.57, df = 7) post-injection. Based on pre-
vious analysis, one-way repeated measures ANOVA and post hoc 
testing comparing CTL vs. 0.05 mmol NMDA revealed a statistically 
significant increase in P13 potential amplitude at 15 min (p < 0.05, 
Figure 4 | intracranial microinjection of NMDA into the PPN increased the 
amplitude of the P13 potential: (A) Mean amplitude difference (μV) from CTL 
amplitude before injection (CTL) and following injection at 5, 10, 15, 25, 35, and 
45 min. Averages after saline (black, n = 17), 0.025 mmol NMDA (red, n = 8), 
0.05 mmol NMDA (blue, n = 12), 0.10 mmol NMDA (green, n = 8), 0.30 mmol 
NMDA (pink, n = 8), and 1.00 mmol NMDA (yellow, n = 8). Significance is 
denoted for two-way ANOVA between groups comparison. Note the significant 
increases in P13 potential amplitude compared to saline at 10, 15, and 35 min 
following 1.00 mmol NMDA (*p < 0.05, **p < 0.01). (B) Mean amplitude 
difference (μV) from CTL amplitude before injection (CTL) and following injection 
at 5, 10, 15, 25, 35, and 45 min. Averages after saline (black, n = 17), 0.10 mmol 
NMDA (green, n = 8), 0.30 mmol NMDA (pink, n = 8), and 1.00 mmol NMDA 
(yellow, n = 8). Significance is denoted for one-way ANOVA within subject 
comparison. Note the significant increase in P13 potential amplitude compared 
to CTL at 10 and 15 min following 0.10 mmol NMDA; 10 and 15 min following 
0.30 mmol NMDA; and 10 and 15 min following 1.00 mmol NMDA (*p < 0.05, 
**p < 0.01). (C) Mean amplitude difference (μV) from CTL amplitude before 
injection (CTL) and following injection at 5, 10, 15, 25, 35, and 45 min. Averages 
after saline (black, n = 17), 0.05 mmol NMDA (blue, n = 12), 0.16 nmol AP5 
(green, n = 6), and 0.05 NMDA after pretreatment with 0.16 nmol AP5 (red, 
n = 5). Significance is denoted for two-way ANOVA between groups 
comparison. Note the significant increase in amplitude of the P13 potential 
following 0.05 mmol NMDA compared to saline, and NMDA pretreated with 
AP5 (*p < 0.05, **p < 0.01).
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Next, the NMDA receptor antagonist AP5 was added before 
NMDA. Figure 5C shows the SR amplitude following injection of 
saline (n = 9), 0.05 mmol NMDA (n = 7), and 0.05 mmol NMDA 
pretreated with 0.16 nmol AP5 (n = 4). Two-way ANOVA with fac-
tors of time and drug revealed no statistical difference at any time 
point between AP5/NMDA and saline or NMDA alone. Based on 
previous analysis, one-way repeated measures ANOVA compar-
ing CTL vs. 0.05 mmol NMDA revealed no statistically significant 
decrease in SR amplitude. One-way ANOVA comparing CTL vs. 
AP5/NMDA also revealed no statistical difference at any time point 
(ns, F = 0.64, df = 3). However, it did appear as if NMDA alone 
decreased the amplitude of the SR and this was blocked by pretreat-
ment with AP5 at 10, 15, and 35 min.
effects of Ka on the p13 potentIal and sr
To test the effects of ICM of KA into the PPN on P13 potential ampli-
tude, saline and four concentrations of KA were injected into the 
PPN and P13 response amplitude was measured following auditory 
0.025 mmol NMDA (ns, F = 0.77, df = 7), 0.05 mmol NMDA (ns, 
F = 0.64, df = 7), 0.10 mmol NMDA (ns, F = 0.76, df = 7), 0.30 mmol 
NMDA (ns, F = 0.72, df = 7), or 1.0 mmol NMDA (ns, F = 1.63, 
df = 7) at any time point. Further statistical testing was performed 
to compare the CTL SR amplitude (before ICM of NMDA) to 
amplitude following ICM at each time point (Figure 5B). One-way 
repeated measures ANOVA comparing CTL vs. each concentration 
of NMDA revealed no statistically significant decrease in SR ampli-
tude between CTL and 0.10 mmol NMDA (ns, F = 1.29, df = 6); 
between CTL and 0.30 mmol NMDA (ns, F = 0.91, df = 5); or 
between CTL and 1.00 mmol NMDA (ns, F = 0.79, df = 3). ICM of 
saline did not result in any significant change in SR amplitude (ns, 
F = 0.94, df = 16). Therefore, ICM of NMDA into the PPN does 
not result in any statistically significant change in the SR following 
an auditory stimulus. However, there does seem to be a decreasing 
trend in SR amplitude 10 min post-injection. This may not have 
reached significance due to the small amplitude of the change and 
the variability between subjects.
Figure 5 | intracranial microinjection of NMDA into the PPN increased the 
amplitude of the Sr: (A) Mean amplitude difference (μV) from CTL amplitude 
recorded before injection (CTL) and following injections at 5, 10, 15, 25, 35, and 
45 min. Averages after saline (black, n = 9), 0.025 mmol NMDA (red, n = 5), 
0.05 mmol NMDA (blue, n = 12), 0.10 mmol NMDA (green, n = 6), 0.30 mmol 
NMDA (pink, n = 6), and 1.00 mmol NMDA (yellow, n = 9). Note the numerical 
decrease in SR amplitude following 0.05, 0.10, and 0.30 mmol NMDA at 10 min 
post-injection. (B) Note the decrease in SR amplitude compared to CTL 
following 0.10 mmol NMDA at 10 min and following 0.30 mmol NMDA at 5, 10, 
and 15 min post-injection. (C) Mean amplitude (μV) from CTL amplitude 
recorded before injection (CTL) and immediately following injection at 5, 10, 15, 
25, 35, and 45 min. Averages after saline (black, n = 9), 0.05 mmol NMDA (blue, 
n = 12), and 0.05 mmol NMDA pretreated with 0.16 nmol AP5 (red, n = 4). Note 
the decrease in the SR amplitude following 0.05 mmol NMDA alone compared 
to saline and this decrease was partially blocked by pretreatment with 0.16 nmol 
AP5. However, this was not statistically significant.
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increases in P13 potential amplitude between CTL and 15 μmol KA 
at 5 min (p < 0.05, F = 2.68, df = 8) post-injection; between CTL and 
20 μmol KA at 5, 35, and 45 min (p < 0.05) and 25 min (p < 0.01, 
F = 5.44, df = 8) post-injection; and between CTL and 30 μmol at 
5 min (p < 0.05, F = 2.06, df = 3) post-injection. ICM of saline did 
not result in any significant change in P13 potential amplitude at any 
time point (ns, F = 0.83, df = 16).
Next, the KA receptor antagonist GAMS was added before KA 
to determine if the increase in P13 potential amplitude could be 
blocked. Figure 6C shows the mean and SE of the amplitude of 
the P13 potential following ICM of saline (n = 17), 0.16 nmol 
GAMS (n = 4), 15 μmol KA (n = 8), and 15 μmol KA pretreated 
with 0.16 nmol GAMS (n = 4). Two-way ANOVA with factors of 
time and drug and post hoc testing revealed statistically significant 
increase in the P13 amplitude following KA compared to KA 
stimuli. Figure 6A shows the mean and SE of the amplitude of the 
P13 potential following ICM of saline (n = 17), 10 μmol KA (n = 8), 
15 μmol KA (n = 8), 20 μmol KA (n = 9), and 30 μmol KA (n = 4). 
Two-way repeated measures ANOVA with factors of time and drug 
concentration and post hoc testing comparing saline vs. each con-
centration of KA revealed a statistically significant increase in P13 
potential amplitude following 15 μmol KA at 5 min (p < 0.05, F = 2.23, 
df = 7) post-injection; 20 μmol KA at 5 and 45 min (p < 0.05) and 
25 and 35 min (p < 0.01, F = 2.73, df = 7) post-injection; 30 μmol at 
5, 45, and 55 min (p < 0.05) and 10, 25, 35 min (p < 0.01, F = 3.04, 
df = 7) post-injection. Further statistical testing was performed to 
compare the CTL P13 potential amplitude (before ICM of KA) to 
the amplitude following ICM at each time point (Figure 6B). One-
way repeated measures ANOVA and post hoc testing comparing 
CTL vs. each concentration of KA revealed statistically significant 
Figure 6 | intracranial microinjection of KA into the PPN increased the 
amplitude of the P13: (A) Mean amplitude difference (μV) from CTL recorded 
before injection (CTL) or 5, 10, 15, 25, 35, and 45 min following injection. 
Averages after saline (black, n = 17), 10 μmol KA (red, n = 8), 15 μmol KA (blue, 
n = 8), 20 μmol KA (green, n = 9), and 30 μmol KA (pink, n = 4). Significance is 
denoted for two-way ANOVA group comparison. Note the significant increases in 
P13 potential amplitude compared to saline at 5 min following 15, 20, and 
30 μmol KA, 10 min following 30 μmol KA, 25 and 35 min following 20 and 
30 μmol KA, and 35 min following 20 and 30 μmol KA (*p < 0.05, **p < 0.01). 
(B) Mean amplitude difference (μV) from CTL recorded before injection (CTL) or 
5, 10, 15, 25, 35, and 45 min following injection. Averages after saline (black, 
n = 17), 15 μmol KA (blue, n = 8), 20 μmol KA (green, n = 9), and 30 μmol KA 
(pink, n = 4). Significance is denoted for one-way ANOVA within subject 
comparison. Note the significant increases in P13 potential amplitude compared 
to CTL at 5 min following 15 μmol KA; 5, 25, 35, and 45 min following 20 μmol 
KA; and at 5 min following 30 μmol KA (*p < 0.05, **p < 0.01). (C) Mean 
amplitude difference (μV) from CTL amplitude recorded before injection (CTL) or 
5, 10, 15, 25, 35, and 45 min following injection. Averages after saline (black, 
n = 17), 0.16 nmol GAMS (green, n = 4), 15 μmol KA (blue, n = 8), and 15 μmol KA 
pretreated with 0.016 nmol GAMS (red, n = 4). The P13 potential amplitude was 
significantly higher following 15 μmol KA alone than following ICM of saline or KA 
pretreated with GAMS at 5 min post-injection (*p < 0.05, **p < 0.01).
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0.16 nmol GLU and the peak effect was at 15 min post-injection. 
However, significant amplitude increases induced by higher con-
centrations of GLU were observed as early as 5 min post-injection. 
The effects of GLU on the amplitude of the P13 potential began 
to return to control levels by 25 min post-injection. Multiple GLU 
receptors may have contributed to the increase in P13 potential 
amplitude, and these receptors may be active at different time 
points. Thus the effects that were observed early (5 min) may 
be due to fast ionotropic receptors, whereas the effects seen later 
(15 min) may be due to slower acting ionotropic and perhaps 
metabotropic receptors.
Intracranial microinjection of the glutamate receptor agonists 
NMDA and KA into the PPN also dose-dependently increased the 
amplitude of the P13 potential. The increase induced by NMDA 
was first observed following 0.05 mmol NMDA and the peak effect 
was at 15 min post-injection. Furthermore, significant increases 
induced by higher concentrations of NMDA were observed as 
early as 10 min post-injection. Following KA, the increase in P13 
potential amplitude was first induced following 15 μmol KA, and 
the peak effect was at 5 min post-injection and the effect waned 
by 15 min post-injection.
There are two aspects of the increase in P13 potential ampli-
tude that are of particular interest. This first is that injection 
of KA at concentrations above 15 μmol produced significant 
increases in P13 potential amplitude as early as 5 min. This is 
supportive of the known functions of KA receptors to mediate 
fast excitatory postsynaptic currents via ionotropic channels 
(Hille, 2001).
The second observation of interest is that KA not only increased 
P13 potential amplitude rapidly, but also appeared to have a 
biphasic effect with significant increases at 25–45 min. That is, 
the initial increase occurred at 5 min, returned toward baseline 
by 10 and 15 min, and then increased again at 25 min for higher 
concentrations of KA at 20 and 30 μmol. Given that KA receptors 
desensitize quickly in response to KA application (Hille, 2001), the 
response is possibly due to secondary effects by metabotropic or 
NMDA receptors. The initial depolarization by KA receptor acti-
vation (increased amplitudes at 5 min) may have released the Mg 
block of voltage gated NMDA receptors, producing a secondary 
increase in P13 potential amplitude at 25 min. However, these later 
effects were not observed following NMDA alone, when the peak 
response was 15 min post-injection, and at 25 min the response 
was not significantly different from saline. Another possibility is 
metabotropic actions of KA receptors (Rodriguez-Moreno and 
Sihra, 2007), which are slower to activate and could account for 
the increase at 25 min.
glu and agonIst effects on sr
In addition to stimulating excitatory ascending projections from 
the PPN, GLU also stimulates inhibitory descending projec-
tions to the CPRF (Davis, 1984; Semba et al., 1990; Koch and 
Schnitzler, 1997), which modulate the SR. We previously reported 
that descending projections from the PPN tend to inhibit large 
neurons involved in mediating the inhibition of postural, usually 
extensor, muscles, but also exciting small neurons presumably 
involved in locomotion (Homma et al., 2002). This mechanism 
was proposed to participate in the atonia of paradoxical sleep, as 
pretreated with GAMS at 5 min (p < 0.05, F = 2.12, df = 7) post-
injection. Based on previous analysis, one-way repeated meas-
ures ANOVA and post hoc testing comparing CTL vs. 15 μmol 
KA revealed a statistically significant increase in P13 potential 
amplitude at 5 min (p < 0.05, F = 2.6828, df = 8). One-way 
ANOVA comparing CTL vs. GAMS/KA revealed no statistically 
significant difference in P13 potential amplitude at any time 
point. Therefore, ICM of KA increased the amplitude of the 
P13 potential and this effect is blocked by pretreatment with 
the antagonist GAMS.
The effect of ICM of KA into the PPN on SR amplitude was also 
measured. Figure 7A shows the mean and SE of the amplitude of 
the SR following saline (n = 9), 15 μmol KA (n = 2), and 20 μmol 
KA (n = 2). One-way repeated measures ANOVA comparing CTL 
vs. each concentration of KA revealed no statistically significant 
decrease in SR amplitude between CTL and any concentration 
of KA at any time point (Figure 7B). Figure 7C shows the SR 
amplitude following ICM of saline (n = 9), 15 μmol KA (n = 2), 
and 15 μmol KA pretreated with GAMS 0.16 nmol (n = 3). ICM 
of GAMS/KA did not result in any significant change in SR ampli-
tude compared to CTL or KA alone at any time point, revealed 
by one and two-way ANOVA, respectively. However, there was 
clearly a trend toward decreased SR amplitude at some points, 
which appears to have been blocked by pretreatment with GAMS. 
Lack of statistical significance could be due to variability in the 
individual recordings.
dIscussIon
The aim of these studies was to determine how specific gluta-
mate receptors in the PPN modulate arousal as manifested by 
the amplitude of the P13 potential in the freely moving ani-
mal. Major findings include (1) ICM of GLU into the PPN of 
the rat dose-dependently increased the amplitude of the P13 
potential and decreased SR amplitude, and (2) ICM of the spe-
cific agonists NMDA and KA increased the amplitude of the 
P13 potential, which was blocked by pretreatment with the 
respective receptor antagonists. NMDA and KA also seemed to 
decrease the amplitude of the SR, but these results were not 
statistically significant.
The temporal relationship between the P13 potential and SR 
has been described previously (Miyazato et al., 1996). An early 
excitation of the SR occurs at 6–9 ms, followed by an inhibitory 
phase at 10–16 ms during the peak P13 response (Figure 1). In 
some animals, a late excitation of the SR at 18–22 ms was also 
observed. It has been proposed that the function of the SR is to 
activate descending reticulospinal systems in order to respond to 
novel input (Miyazato et al., 1996). The P13 potential inhibition of 
the SR was proposed to function to reset ongoing motor programs 
in order to mount a response (Miyazato et al., 1996).
glu and agonIst effects on the p13 potentIal
The PPN sends cholinergic projections to the Pf and other nuclei 
in the ILT (Sofroniew et al., 1985; Hallanger et al., 1987). The P13 
potential, recorded from the Vx, appears to reflect this output 
from the PPN (Miyazato et al., 1995, 1996, 1999a,c; Teneud et al., 
2000). These results show that GLU dose-dependently increased the 
amplitude of the P13 potential. This increase was first induced by 
www.frontiersin.org January 2011 | Volume 2 | Article 3 | 11
Simon et al. Glutamatergic effects on the P13
was not statistically significant. This suggests that the descend-
ing inhibitory effect by PPN may require activation of multiple 
types of glutamate receptors, including ionotropic and perhaps 
metabotropic receptors.
dIsorders InvolvIng attentIonal and postural dIsturbances
Dysregulation of the RAS has been implicated in a number of 
psychiatric disorders characterized by an increase in vigilance 
and REM sleep drive (Garcia-Rill et al., 2003). The P50 poten-
tial (amplitude and/or habituation) and SR in humans has been 
described as potentiated in patients with Schizophrenia (decreased 
habituation), Post Traumatic Stress Disorder (decreased habitua-
tion), Parkinson’s (increased amplitude and decreased habitua-
tion), and Huntington’s (decreased amplitude and habituation) 
diseases ( Freedman et al., 1983; Buchwald et al., 1989; Gillette 
et al., 1997; Teo et al., 1997; Skinner et al., 1999; Arnfred et al., 2003; 
well as in the modulation of the SR, in which inhibition of exten-
sors (the SR is a flexor response) primes the system to “fight or 
flee.” ICM of GLU into the PPN resulted in a significant decrease 
in the amplitude of the SR as early as 5 min post-injection. It is 
interesting to note that ICM of GLU decreased the amplitude of 
the SR potential in a dose-dependent fashion (Figure 2) at con-
centrations of 0.06, 0.16, and 0.30 nmol. However, the highest dose 
of 0.48 nmol was not statistically different from saline. The PPN 
contains a number of GABAergic interneurons ( Mena-Segovia 
et al., 2009; Wang and Morales, 2009). Perhaps an excess of GLU 
release into the PPN excites the numerous GABAergic interneu-
rons present in the PPN, resulting in inhibition of output neurons, 
disinhibition of the neurons in the CPRF, and no change in the 
SR. Injection of the glutamate receptor agonists NMDA or KA 
into the PPN resulted in a general decrease in the amplitude of 
the SR as early as 5 min post-injection, although this decrease 
Figure 7 | intracranial microinjection of KA into the PPN decreased the 
Sr amplitude, an effect Blocked by Pretreatment with gAMS: (A) Mean 
amplitude difference (μV) from CTL amplitude recorded before injection (CTL) 
and 5, 10, 15, 25, 35, and 45 min following injection. Averages after saline 
(black, n = 9), 15 μmol KA (blue, n = 2) and 20 μmol KA (green, n = 2). Note the 
numerical decreases in amplitude of the SR compared to saline after 5, 15, 25, 
and 35 min post-injection, but these responses were not significant. (B) 
Averages after saline (black, n = 9), 15 μmol KA (blue, n = 2) and 20 μmol KA 
(green, n = 2). Note the numerical decrease in SR amplitude at 5, 10, and 
35 min following 15 μmol KA, and at 5, 10, 15, 25, and 35 min following 
20 μmol KA. (C) Mean amplitude difference (μV) from CTL amplitude recorded 
before injection (CTL) and 5, 10, 15, 25, 35, and 45 min following injection. 
Averages after saline (black, n = 9), 15 μmol KA (blue, n = 2), and 15 μmol KA 
pretreated with 0.16 nmol GAMS (red, n = 3). Note the decrease in SR 
amplitude following 15 μmol KA and this was blocked by pretreatment with 
GAMS (results not significant).
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